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Summary This study examined the expression of epidermal growth factor (EGF) cell-surface receptors, the
response to exogenous ligand and the autocrine production of transforming growth factor a (TGF-a) in
normal and carcinoma-derived human oral keratinocytes. One of eight malignant cell lines overexpressed EGF
receptors, while the remainder expressed receptor numbers similar to normal cells. Exogenous EGF stimulated
incorporation of tritiated thymidine in a dose-dependent manner. In keratinocytes expressing normal numbers
of EGF receptors, the cellular response to exogenous EGF correlated positively with total EGF receptor
number. SCC-derived keratinocytes produced more TGF-a than normal cells. There was no statistical
correlation between the autocrine production of TGF-a, EGF cell-surface receptor expression and cellular
response to exogenous EGF. While the growth-stimulatory effects of exogenous TGF-a were inhibited by the
addition of a neutralising antibody, the presence of this antibody in conditioned medium failed to produce a
similar decrease in growth. The results indicate that overexpression of EGF receptors is not an invariable
characteristic of human oral squamous carcinoma-derived cell lines. Further, the contribution of TGF-a to the
growth of normal and carcinoma-derived human oral keratinocytes in vitro may be less significant than
previously documented.
Epidermal growth factor (EGF) is perhaps one of the best-
characterised cytokines that has been studied in the context
of cell growth. EGF mediates its response through interac-
tion with specific cell-surface receptors which are expressed as
both low- and high-affinity forms, the latter purportedly
being formed from the non-covalent association of two or
more receptor monomers; activation of the EGF receptor
complex stimulates tyrosine kinase activity, resulting in signal
transduction (Carpenter & Cohen, 1990).
Overexpression of the EGF receptor is considered by some
to be the hallmark of human squamous cell carcinomas
(Ozanne et al., 1986) and, in certain tumours, correlates with
poor clinical prognosis (Gullick et al., 1991). In tumours of
the head and neck, EGF receptor expression has been ex-
amined predominantly using immunocytochemical techniques
(Partridge et al., 1988; Sakai et al., 1989; Karsley et al., 1990;
Shirasuna et al., 1991) and by Southern and Northern blot
hybridisation (Yamamoto et al., 1986; Eisbruch et al., 1987;
Ishitoya et al., 1989; Ebrahim El-Zayat et al., 1991; Saranath
et al., 1992). A consensus of this work indicates that EGF
receptor overexpression is not always attributable to gene
amplification and/or mRNA overexpression and may not
necessarily correlate to poor clinical prognosis. The biological
significance and the factors that control EGF receptor ex-
pression, therefore, remain an enigma.
The discovery that many tumours which express EGF
receptors also produce transforming growth factor a (TGF-a),
a potent agonist of the EGF receptor (Massague, 1983),
resulted in the attractive autocine hypothesis of malignant
cell growth and transformation (Sporn & Todaro, 1980).
Indeed, there is compelling evidence that TGF-a is involved
in oncogenesis because the protein is not only secreted by a
variety of experimental and naturally occurring tumours and
cell lines (Derynck et al., 1987; Anzano et al., 1989; Imanishi
et al., 1989) but also induces epithelial hyperplasia in
keratinocytes transfected with the TGF-a gene and in trans-
genic mice overexpressing TGF-a in the basal epidermal layer
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(Finzi et al., 1988; Sandgren et al., 1990). Complete malig-
nant transformation, however, requires a second defect in the
autocrine loop (Cross & Dexter, 1991). The nature of such a
second defect is unknown but it seems likely to involve the
signal transduction pathway, possibly by way of overexpres-
sion of the EGF receptor. It is not clear whether tumour cells
that overproduce TGF-a concurrently express elevated
numbers of EGF receptors.
There is now good evidence that the development and
progression of epithelial malignancy is associated with the
abrogation of normal growth control mechanisms. We have
shown, for example, that carcinogen-treated (Game et al.,
1990) and Ha-ras-transfected (Game et al., 1992) keratino-
cytes are independent of EGF-induced growth regulation.
These findings would appear to be contradictory to a growth-
stimulatory role of TGF-a in tumour development and have
been explained by others in terms of the down-regulation of
EGF receptors by endogenous TGF-a (Ciardiello et al.,
1989). It is now essential not only to extend the observations
made in different experimental systems to a situation closer
to human malignancy but, also, to correlate the different
parameters in the same tumour cell lines.
The purpose of the present study, therefore, was to investi-
gate the expression of EGF cell-surface receptors, TGF-a
autocrine production and the response to exogenous EGF in
cell lines derived from untreated human oral squamous cell
carcinomas.
Materials and methods
Tissues/cultured cells
Untreated primary human oral squamous cell carcinomas
(Table I), normal gingival mucosa from the third molar
region (n = 10) and normal buccal mucosa (n = 4) were
divided and either fixed in neutral formalin (prior to being
routinely processed to paraffin wax), snap frozen in liquid
nitrogen or used to establish cultured cells; cultures of nor-
mal oral keratinocytes were derived from gingivectomy speci-
mens (Prime et al., 1990; Parkinson & Yeudall, 1991).
Biopsy material used to establish cell lines was soaked
briefly in absolute alcohol (2-3 s) and then washed (x 2) in
Dulbecco's modified Eagle medium (DMEM) containing
200 i.u. ml1' penicillin, 200jgml1' streptomycin and
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Table I Features of primary human oral carcinomas and cell linesa
Age of STNMPC
Cell line patient (years) Sex Siteb clinical grade Tumorigenicityd
103 32 M T I T
157 84 M BM II NT
314 82 M FOM II T
357 74 M T I T
376 40 F FOM III NT
400 55 F AP II NT
413 53 F BM II NT
T45 61 M BM NAe T
aPrime et al. (1990); Parkinson & Yeudall (1991). bT, tongue; BM, buccal mucosa;
FOM, floor of mouth; AP, alveolar process. 'Untreated primary oral carcinomas were
classified clinically according to their site of origin (S), tumour size (T), lymph node
(N) and metastatic (M) involvement and tumour pathology (P). Each parameter was
'weighted' numerically and the maximum index of severity was used to express the
STNMP clinical stage. The 5-year survival rate is 51.5% for grade 1, 25.3% for grade
II, 21.5% for grade III and 8.3% for grade IV (Henk, 1985). dApproximately 1 x 107
cells were transplanted subcutaneously into 4- to 6-week-old, male athymic (nu/nu;
Balb/C) mice. Animals were killed following tumour formation or after 6 months. T,
tumorigenic; NT, non-tumorigenic. Clones of the parental cell lines showed a similar
pattern of tumorigenicity in athymic mice with the exception of H400, where a clonal
cell line was tumorigenic. eNA, information not available.
5 iLg ml' fungizone. Tissues were minced, washed (x 3),
resuspended in complete medium [DMEM containing 10%
(v/v) fetal calf serum (FCS), 10 i.u. ml-' penicillin,
100 Ig mml' streptomycin, 2.5 jgml-1 fungizone, 0.075%
additional sodium bicarbonate, 0.6 mg ml' additional L-
glutamine, 0.5 fg ml' hydrocortisone and 10 ng ml'
cholera toxin], and seeded into prepared 60-mm tissue culture
Petri dishes containing 2 x 105 mitomycin C-treated 3T3
fibroblasts. Similar techniques were used for the culture of
normal keratinocytes, except that the epithelium was first
removed from the underlying connective tissue by incubation
in 5ml of trypsin type III (Sigma) containing 100i.u.ml-'
penicillin, lOOutgml-' streptomycin and 2.5,ugml-' fun-
gizone, initially at 4'C for 12 h and then at 37°C for 30 min.
All cultures were incubated in a humidified atmosphere of
5% carbon dioxide/95% air at 37°C and the medium was
changed twice weekly. In later culture passages, cell lines
were grown in the absence of 3T3 fibroblast support and in
DMEM containing 10% (v/v) FCS and free of all antibiotics.
Immunocytochemical staining
Details of the monoclonal antibodies reactive with epitopes
on the protein portion of the extracellular domain of the
EGF receptor are presented in Table II. Immunocyto-
chemical staining was performed using a biotin-streptavidin
immunoperoxidase technique (StrAviGen; Biogenex) on
acetone-fixed spot preparations of cell lines (Deacon et al.,
1991) or trypsin-treated formalin-fixed paraffin sections of
the primary tumours or normal human oral mucosa. In brief,
cell preparations and sections were incubated sequentially
with anti-EGF receptor antibody and biotinylated anti-
mouse immunoglobulin [BioGenex; 1:100 dilution in 1O mM
phosphate-buffered saline (PBS) pH 7.6 containing 1% (v/v)
normal human serum, 1 h at room temperature). Sections
were washed in dilution buffer between each layer. Reaction
products were developed by immersing slides in 3,3'-diamino-
benzidine reagent (5 min) and subsequently enhanced by
treatment with 0.5% copper sulphate (w/v in saline) for
5 min. Stained cell preparations and sections were lightly
counterstained in Meyer's haematoxylin and mounted in
Xam.
Negative controls included replacement of the primary
layer with non-immune mouse immunoglobulin (1 or
3 fig ml-1), a monoclonal antibody of irrelevant specificity
but similar IgG subclass to that of the test monoclonal
antibody (MRC OX-6, IgGI, anti-rat I-A; MRC OX-40,
IgG2b, anti-rat T cells; 1 or 3 fig ml-'; Serotec) and PBS.
Tissues were also stained for keratin (clone LP34, Dako,
1:200, 1 h) in order to clearly define small areas of tumour
epithelium and to act as a positive 'tissue' control.
Spot preparations of cell lines stained with EGFR-1 were
evaluated by one individual (J.B.M.) without prior
knowledge of the results from the radioligand binding
studies. Cell counts were performed at a magnification of
x 400 and the highest antibody dilution resulting in staining
of > 50% and > 5% of cells from each cell line was deter-
mined. A minimum of 200 cells were evaluated from each
stained preparation and positive cells identified as those
exhibiting a clear brown membrane staining pattern. Sections
of the primary tumours were examined subjectively without
prior knowledge of the origin of each cell line.
Binding and incorporation assays
Previous studies have described methods to quantify EGF
receptor number and affinity (Game et al., 1990).
Cell proliferation in response to exogenous EGF was
measured using tritiated thymidine incorporation assays
(Game et al., 1990), and this was extended to include
exogenous TGF-a (1 ng ml-' and 10 ng ml-'). Cells were
seeded at low density (5 x 104 cells per well) into 24-well
Table II Details of mouse monoclonal antibodies to EGF receptor
IgG Trypsin Incubation
Antibody subclass Dilution Tissue digestion time/temp. Source
EGFR-la IgG2b 1:50-1,600 Cell spot preps No 1 h at room Amersham
temperature
E30b IgGI 1:60' Formalin-paraffin Yesd 2 h at room Biogenex (Bio
sections temperature' then Diagnostics)
overnight at 4'C
'EGFR-1 shows poor reactivity with formalin-fixed paraffin sections compared with frozen sections. bE30 detects EGF receptors
in fresh-frozen and formalin-fixed paraffin-embedded tissue. cOptimum dilution determined by chequerboard titration. dO.1% (w/v
in PBS) Difco 1:250 grade trypsin; 30 min at room temperature. eSome sections were only subjected to a 2-hr incubation.10 S.S. PRIME et al.
culture plates, and normal keratinocytes were seeded into
60-mm cell culture dishes (1 x 105 cells per dish). After
48-72 h growth in complete medium, the serum concentra-
tion was reduced to 1% (v/v) FCS and EGF (0.01-
1.0 ng ml-') was added. After 24 h, the ligand and medium
were replaced with 0.5 ml of DMEM plus 1% (v/v) FBS and
10 ,Ll of methyl-[3H]thymidine (2 Cimmol-', 2.5tiCi per well;
Amersham, UK). The cells were incubated in a humidified
atmosphere of 5% carbon dioxide/95% air at 37°C for 2 h,
washed (x 3) in ice-cold PBS and fixed in 5% (v/v) trich-
loracetic acid at 4°C for 10 min followed by three washes
with distilled water. The cells were solubilised with 0.5M
sodium hydroxide (1 ml per well) at 37°C for 2 h, and this
solution was added to 4 ml scintillant prior to determining
the radioactivity in a beta scintillation counter (LKB Rack-
beta).
Autocrine production of TGF-.a
TGF- o was isolated from conditioned media using ion-
exchange chromatography and then quantified by competi-
tion binding assays (Donnelly et al., 1993). The degree of
inhibition of 50-jLl aliquots was compared with the inhibition
values obtained using a range of unlabelled growth factor
concentrations (EGF 0.083-0.42 nM). TGF-a was distin-
guished from EGF in conditioned media by immunoprecipi-
tation, Western blotting and chemiluminescence, as
previously described (Donnelly et al., 1993).
Neutralisation ofTGF-c
Serum-free culture medium was collected from 107 H103 cells
at 80% confluence over 48 h, filtered through a 0.45-tim filter
(Millipore) and added to H103 cells in culture. Cell prolifera-
tion was measured as previously described (Game et al.,
1990). In certain experiments, a 10-fold molar excess of a
neutralising antibody to TGF-a (Ab-3, Oncogene Science)
was added to culture medium to block ligand activity.
Similar techniques were used to block the activity of
exogenously added TGF-o.
Statistics
Statistical analyses were performed using the Mann-Whitney
test with P <0.05 being taken as statistically significant.
Results
Immunocytochemistry
Antibody E30, directed towards the extracellular domain of
the EGF receptor, gave intense membranous staining of
epithelial cells within normal gingival and buccal mucosa
which progressively diminished from the basal toward the
most superficial layers (Figure la). When the normal oral
mucosa was subjected to a reduced (2 h only) incubation
with the primary antibody, the buccal epithelium stained
more intensely than that of gingiva.
Six of seven primary carcinomas (T45 tissue was not
available) demonstrated a consistent and strong membrane-
staining pattern for EGF receptors (Figure lb and c).
Invading islands of malignant epithelium showed maximal
reactivity at the periphery adjacent to the connective tissue
and gradual loss of reactivity in areas of squamous differenti-
ation. A similar differentiation-associated loss of staining was
also demonstrable in uninvolved overlying mucosal epi-
thelium present in five specimens. Subjectively, staining
appeared to be of a lower intensity in normal compared with
tumour epithelium. A single tumour, the source of the cell
line H376, showed poor patchy staining for the EGF recep-
tor with the majority of cells being negative or weakly
positive (Figure Id).
Seven cell lines (T45 was not examined) demonstrated a
membrane pattern of staining. There was a great variation in
the proportion of positive cells and no cell line showed 100%
cellular reactivity at any of the antibody dilutions tested.
EGFreceptor number and affinity
The number and affinity of EGF receptors in the normal and
SCC-derived human oral keratinocytes is shown in Table III.
One of eight malignant lines overexpressed EGF receptors
(H413: 1,209,872), while the remainder expressed similar
numbers of EGF receptors to normal keratinocytes (malig-
nant cell lines, mean 456,189; normal, 534,938). The pattern
of total EGF receptor expression predominantly reflected the
number of low-affinity receptors, although the affinity of this
receptor type was higher in the malignant cells (mean
kD= 3.8 nM) than normal 5 (kD =16.4 nM). Four SCC lines
(H103, H314, H400, H413) did not express high-affinity EGF
receptors; the remaining SCC lines and normal keratinocytes
expressed high-affinity receptors of similar affinity.
The total number of EGF receptors as demonstrated by
radioligand binding studies (H413>H357>H400 = H103 =
HI57> H376 = H314) broadly corresponded with the dilu-
tion of anti-EGF receptor antibody which stained approxi-
mately 50% (H400=H103>H413=H357>H157=H376
=H314) and 5% (H103=H357>H413=H400> H157
= H376>H314) of cells.
Response to exogenous EGF
The effect of EGF on tritiated thymidine incorporation in the
normal and SCC-derived human oral keratinocytes is shown
in Figure 2. EGF stimulated thymidine incorporation in both
the normal and malignant keratinocytes in a dose-dependent
manner (data not shown). The majority of the malignant cell
lines were more sensitive to EGF stimulation than normal
cells, particularly using lower EGF concentrations
(< 0.lIgml-').
The response of the normal and malignant keratinocytes to
EGF (1.0 ng ml-l) correlated significantly to the total
number of EGF receptors: cells that expressed more EGF
receptors demonstrated an increased response to exogenous
EGF and vice versa (Figure 3; r = 0.77, P <0.03; H413 was
excluded from the statistical analysis). The cellular response
to exogenous EGF was not examined in the context of the
different EGF receptor affinities because only four malignant
cell lines expressed high-affinity receptors and the number of
low-affinity receptors broadly corresponded to the total
number of EGF receptors.
TGF-c production
Both normal and malignant keratinocytes produced TGF-a
and not EGF, as demonstrated by Western blot analysis to
anti-TGF-a and anti-EGF antibodies (data not shown). In
general, cell lines of SCC origin produced more TGF-a
(mean: 40.1 pg 10-6 cells 48 h-') than normal controls
(15.2 pg 10-6 cells 48 h-') (Figure 4).
In general, cell lines producing more TGF-o expressed
fewer EGF receptors (and vice versa), but there was no
statistical correlation between these parameters. There was
no relationship between the autocrine production of TGF-x
and the response of the cell lines to exogenous EGF. Further,
TGF-a production was unrelated to both the clinical grade of
the original tumour and the tumorigenicity of the cultured
cells in athymic mice.
Neutralisation ofTGF-c
The addition of exogenous EGF (1 ngml-') and TGF-a
(10 ng ml-') for 24 h stimulated H103 cells by some 10% and
20% respectively, and this effect was partially blocked by the
addition of a neutralising antibody to TGF-a; the inclusion
of this antibody in conditioned medium failed to decrease
[H]thymidine incorporation below control levels (Figure Sa).
When this experiment was repeated over a 48-h period to
examine the effect ofendogenous TGF-a on actively growingEGF AND TGF-a IN HUMAN ORAL CARCINOMA 11
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Figure 1 The histological appearance of normal and untreated primary squamous cell carcinoma stained with the E30 anti-EGF
receptor monoclonal antibody. a, Normal gingival tissue. b and c, Carcinoma tissue from which, b, H103 and, c, H400 were derived
showing strong membranous staining and loss of reactivity associated with keratinocyte differentiation. d, Carcinoma tissue from
which H376 was derived showing strong reactivity of the overlying epithelium and weakly positive tumour cells in the underlying
connective tissue. Bar = 15 tLm.
Table III EGF cell-surface receptor expression in normal and malignant human oral keratinocytes
EGF receptors'
High Low Dilution of EGF receptor
Number Affinity Number Affinity antibody staining
Cell line B..x KD (nM) B. KD (nM) Total 50% cells 5% cells
H103 - - 576,500 1.7 576,500 1:900 1:1400
H157 29,690 0.4 374,049 8.7 403,739 1:200 1:900
H314 - - 283,135 2.4 283,135 1:200 1:400
H357 139,356 0.2 707,849 3.0 847,205 1:600 1:1400
H376 60,826 0.3 244,694 2.8 305,520 1:200 1:900
H400 - - 483,152 1.2 483,152 1:900 1:1200
H413 - - 1,209,872 2.1 1,209,872 1:600 1:1200
T45 63,510 0.31 240,560 8.2 294,070 NDC ND
Normalb 17,685 0.3 534,938 16.4 552,623 ND ND
LICR/LON/HN5 306,660 0.18 14,533,000 12.4 14,839,660 - -
L1CR/LON/HN2 47,800 0.17 397,000 4.2 444,000 - -
L1CR/LON/HN6 137,436 0.16 1,443,000 7.4 1,580,436 - -
aData are the mean of three or more separate experiments; cells were assayed at passage 15. bData are the mean of
two samples; cells were assayed at passage 2. CND, not done. Standard error of the kinetic parameters (not shown)
was < 10%.
a12 S.S. PRIME et al.
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Figure 2 Tritiated thymidine incorporation in normal and
carcinoma-derived human oral keratinocytes following incubation
with EGF [0.01-1.0 ng per ml of culture medium containing 1%
(v/v) FCS]. The results are expressed as a percentage of the
control in which EGF was omitted. Data points are the mean of
quadruplicate wells in two separate experiments. Standard devia-
tions were less than 5%.
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Figure 3 Correlation between the response of the normal and
carcinoma-derived human oral keratinocytes to EGF [1.0 ng per
ml of culture medium containing 1% (v/v) FCS] and the total
number of EGF cell-surface receptors. H413 was excluded from
the statistical analysis.
cells (Figure Sb), the proliferation of H103 cells progressively
decreased in serum-free medium and remained approximately
constant in conditioned medium. The addition of anti-TGF-o
antibody to both the serum-free and conditioned medium
experiments failed to inhibit cell proliferation.
Discussion
This study correlated the expression of EGF cell-surface
receptors, the response to exogenous ligand and the autocrine
production of TGF-x in normal and carcinoma-derived
human oral keratinocytes.
The immunocytochemical pattern of EGF receptor expres-
sion in the tissues from which the cell lines were derived in
the present study was differentiation related in that there was
marked staining in basal epithelial cells and diminished reac-
tivity in areas of squamous differentiation; this confirms
previous observations (Partridge et al., 1988; Sakai et al.,
1990; Kearsley et al., 1990; Shirasuna et al., 1991). The
maximum dilution of antibody staining 50% and 5% of
cultured cells in the present study broadly corresponded to
the profiles of EGF receptor number as shown in the radio-
Figure 4 Autocrine production of TGF-a by the normal and
carcinoma-derived human oral keratinocytes. The results reflect
the mean of samples assayed in triplicate.
ligand binding studies, findings that are consistent with
previous observations (Henzen-Logmans et al., 1992). The
data indicate no major inconsistencies between immunoreac-
tive and ligand-binding receptor profiles. These findings sug-
gest that endogenous TGF-o does not block EGF receptor
expression. This proposal is supported by the fact that
neither the EGFR-1 nor the E30 monoclonal antibodies com-
pete with EGF for the ligand binding site and, also, by the
observation in the present study that there was no relation-
ship between endogenous TGF-o production and EGF recep-
tor expression. Nevertheless, discrepancies between the
ligand-binding and antibody dilution data (H103 and H400)
were evident in the present study, and it may be that
radioimmunoassays would clarify this situation.
A number of studies have shown that overexpression of
EGF receptors is common in human squamous cell car-
cinomas. In the present study, we examined three cell lines
(LICR-LON-HN2, HN5 and -HN6) for which the EGF
receptor profile had been reported (Cowley et al., 1986). Our
data broadly corresponded to those of Cowley et al. (1986),
thereby verifying the EGF receptor data in the present study.
The EGF receptor numbers of the normal oral keratinocytes
in this study were slightly higher than previously reported
(5.5 x 105 vs 2.8 x 105 receptors per cell; Cowley et al., 1986),
but we believe this to reflect inter-experimental variation and,
possibly, site variation; the normal keratinocytes of the pre-
sent study were gingival in origin, whereas those of Cowley et
al. (1986) were derived from normal human adult skin. Pre-
liminary data in the present study indicate that there may be
a site variation concerning the expression of EGF receptor
within human oral mucosa. Gingival epithelium, for example,
stained less than buccal mucosal epithelium using the ED30
monoclonal antibody, a finding that warrants further investi-
gation with ligand binding studies.
The results of the present study indicate that overexpres-
sion of EGF receptors may not be an invariable character-
istic of human oral squamous cell carcinomas; only one
(H413) of eight oral carcinoma cell lines overexpressed EGF
receptors. Even if the EGF receptor numbers of the normal
keratinocytes in this study were at the level previously
documented (2.8 x 105 receptors per cell; Cowley et al.,
1986), then still only one (H413) of eight malignant cell lines
showed marked elevation of EGF receptor number and four
(H103, H157, H357, H400) cell lines demonstrated minimal
increases in EGF receptor numbers. The mechanism of EGF
receptor overexpression is unknown. Recent evidence sug-
gests that human carcinoma cell lines fail to down-regulate
EGF receptors (Reiss et al., 1991; Gilligan et al., 1992).
Recent studies indicate that serine phosphorylation within
the C-terminal domain of the receptor may be one mechan-
ism to regulate EGF receptor activity (Countaway et al.,
1992), and Theroux et al. (1992) have shown that mutational
removal of this negative regulatory site causes potentiation of
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a known. Other studies have shown that structural or
numerical alterations of chromosome 7 are associated with
enhanced expression of EGF receptors (Korc et al., 1986;
Woloschak et al., 1986).
In the present study, exogenous EGF at concentrations of
0.01-1.0 ng ml- stimulated the normal and malignant
keratinocytes in a dose-dependent manner. The variable re-
sponse of the different cell lines to exogenous EGF may I-_ _ __ reflect the heterogeneous nature of the cell populations as
indicated by the immunocytochemical data. The present
-' '-- --- F F - - study was carried out using early-passage cultures which, by
necessity, had not been cloned. However, it is suggested that
high-passage cultures and/or cloning is likely to select for
A B C D E F cells expressing a specific EGF receptor phenotype and may
Experimental protocol not be a true representation of carcinoma cells in vivo.
Previous studies have shown that, in cell lines showing
b overexpression of EGF receptors, cell growth is stimulated
by lower concentrations of EGF (1.0 ng ml-') but inhibited
using higher EGF concentrations (>1O ng ml') (Cowley et
al., 1984; Kawamoto et al., 1984; Kamata et al., 1986;
Rabiasz et al., 1992). Kawamoto et al. (1984) explained this
biphasic phenomenon by the presence of heterogeneous
receptors; high-affinity EGF receptors were relevant to
growth stimulation, while low-affinity receptors accounted for
growth inhibition. In the present study, there was no rela-
tionship between EGF receptor affinity and the uptake of
tritiated thymidine. What was evident in the cell lines with
normal EGF receptor expression, however, was that the total
EGF receptor number correlated positively to the response to
A A B C D E A B C D E 1.0 ng ml-' exogenous EGF. H413, which overexpressed
0 h 24 h 48 h EGF receptors, did not exhibit an enhanced response to
exogenous EGF. The results suggest that overexpression of
EGF receptors may not confer an enhanced sensitivity to
Tritiated thymidine incorporation in H103 cells cul- exogenous ligand. The constitutive activation of the receptor
h in medium containing 1% (v/v) FCS (A,D) in the (Weiner et al., 1989), however, cannot be excluded as a
r presence of exogenous EGF (I ng ml-'; B), TGF- mechanism imparting a selective growth advantage to these
; C) or TGF-a and a 10-fold molar excess of cells.
intibody to TGF-ca (D). Cells were also cultured with The criteria to validate autocrine growth factor control
*nditioned medium from H103 in the absence (E) or include not only the stimulation of growth by the addition of
of the neutralising antibody. The results are ex- ligand and the presence of cell-surface receptors specific for
percentage of the control in which the ligand and/or ercentage ofthe control in which thelithe ligand, but also the secretion of the growth factor ligand omitted. b, Tritiated thymidine incorporation in '
iltured for up to 48 h in 10% FCS (A), serum-free and the inhlbitlon of growth by antlbodies whIch specifically
and C) and conditioned medium (D and E). Cells block the biological action of that ligand. In the present
Itured in the presence of a I0-fold molar excess of study, the majority of oral carcinoma-derived cell lines pro-
.ntibody in serum-free medium (C) and conditioned duced more TGF-o than normal keratinocytes (exception
The results are expressed as thymidine incorporation H400), findings which support previous observations in a
ta points are the mean of triplicate wells in three variety of tumour cell lines (Anzano et al., 1989; Imanishi et
riments. Bar= standard deviation, where not shown al., 1989). In contrast to previous work in gastrointestinal
°. tumours (Yonemura et al., 1992; Modjtahedi et al., 1992),
there was no obvious relationship in the present study
between the autocrine production of TGF-oa and either the
clinical grade of the original tumour or the tumorigenicity of
uction by the EGF receptor. It is currently not the cell lines following transplantation to athymic mice.
her a similar mechanism is active in human While there was no statistical correlation between TGF-cx
production and EGF receptor expression in the present
ect to receptor synthesis, EGF receptor gene study, there was a distinct trend that cell lines that produced
in head and neck cancer is highly variable more TGF-cz expressed fewer EGF receptors. Similar findings
et al., 1986; Eisbruch et al., 1987; Ishitoya et al., have been reported previously (Partridge et al., 1989) and
not always associated with enhanced gene ex- suggest a down-regulation of EGF receptors following the
,rahim El-Zayat et al., 1991). Furthermore, a autocrine production of TGF-cz. In the present study
has shown that EGF receptor gene amplification exogenous TGF-cz stimulated cell growth of H103, and this
f Indian origin with oropharyngeal cancer does effect was partly blocked by the addition of a neutralising
with the clinicopathological parameters of the antibody. However, the presence of neutralising antibody in
Saranath et al., 1992). In the present study, the conditioned culture medium failed to decrease cell prolifera-
57, H314, H357, H400 and T45 showed marked tion to any measurable extent, suggesting that the effects of
of the EGF receptor gene, while there was an endogenously secreted ligand were minimal. It may be that
ene amplification in H103, H376 and H413 (V. endogenous TGF-a is stimulatory only in conditions of active
in preparation). The data indicate that gene cell growth, and our data cannot exclude this possibility,
does not reflect cell-surface receptor numbers particularly as cell proliferation of H103 remained approxi-
e possibility that there may be a transcriptional mately constant during 48 h in conditioned medium. How-
ial defect. We have shown recently that chromo- ever, the effect of biologically active, membrane-bound TGF-
)oints are present in close proximity to the EGF a (Brachmann et al., 1989; Wong et al., 1989) may be a
on chromosome 7 in H376 and H413 (Patel et significant autocrine growth regulator. The neutralising
Lt whether these defects contribute to the expres- activity of the anti-ligand antibody used in this study may
receptors in these cell lines is currently un- require the exposure of a particular epitope which is possibly
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masked in the membrane-bound form of TGF-a. A more
efficient way to block growth stimulation by both membrane-
bound and secreted ligand may be the use of an anti-EGF
receptor antibody (Modjtahedi et al., 1993).
In conclusion, the results of this study show that over-
expression of EGF receptors was not an invariable charac-
teristic of human oral squamous carcinoma-derived cell lines.
The overproduction of TGF-a occurred commonly in the
carcinoma-derived cell lines, but its role as an autocrine
regulator of cell growth in vitro remains questionable.
The authors wish to thank Mr D. Coles and his staff and Ms Gillian
Mason for their excellent technical assistance and Mrs K. Parkes for
efficient typing of the manuscript. The authors are grateful to Profes-
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study was supported by Denman's Charitable Trust.
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